Press release
Dementia Associated With Alzheimer's Disease Pipeline Drugs Report 2025: A Strategic Overview of Clinical Advancements and Drug Pipeline Growth by DelveInsight
Explore our latest breakthroughs in Dementia Associated With Alzheimer's Disease Research. Learn more about our innovative pipeline today! @ Dementia Associated With Alzheimer's Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Dementia Associated With Alzheimer's Disease Pipeline Report
* On 26 September 2025, Bristol-Myers Squibb conducted a study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
* On 25 September 2025, MapLight Therapeutics organized a study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).
* DelveInsight's Dementia Associated With Alzheimer's Disease pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Dementia Associated With Alzheimer's Disease treatment.
* The leading Dementia Associated With Alzheimer's Disease Companies such as BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.
* Promising Dementia Associated With Alzheimer's Disease Pipeline Therapies such as ITI-1284, Brexpiprazole, ONO-2020, ML-007C-MA, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), aripiprazole, PYM50028, Crenezumab, and others.
Stay informed about the cutting-edge advancements in Dementia Associated With Alzheimer's Disease treatments. Download for updates and be a part of the revolution in Central Nervous System care @ Dementia Associated With Alzheimer's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dementia Associated With Alzheimer's Disease Overview
Dementia is a general term used to describe a significant decline in cognitive ability that interferes with a person's activities of daily living. Alzheimer disease (AD) is the most prevalent type of dementia, accounting for at least two-thirds of cases in individuals aged 65 and older. AD is a neurodegenerative condition with insidious onset and progressive impairment of behavioral and cognitive functions. These functions include memory, comprehension, language, attention, reasoning, and judgment. While AD does not directly cause death, it substantially raises vulnerability to other complications, which can eventually lead to a person's death.
Dementia Associated With Alzheimer's Disease Emerging Drugs Profile
* NE3107: BioVie
NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-B). NFB is activated by amyloid beta and tau - two proteins that form toxic clumps that contribute to Alzheimer's - and by the pro-inflammatory molecules that it stimulates, leading to chronic inflammation. NE3107 was found to have no immunosuppressive effects and to block ERK- and NF-B-induced inflammation without suppressing their functions involved in maintaining overall balance, such as insulin signaling and nerve cell growth and survival. Currently, the drug is in Phase III stage of development for the treatment of Alzheimer Disease.
* AMX0035: Amylyx Pharmaceuticals Inc
AMX0035 is an investigational, oral, fixed-dose combination of sodium Phenylbutyrate (PB) and Taurursodiol (TURSO). This combination therapy is designed to reduce neuronal death through two mechanisms: sodium phenylbutyrate decreases Endoplasmic Reticulum (ER) stress (by upregulating the master chaperone regulator DJ-1) and TUDCA mitigates mitochondrial dysfunction (by incorporating into the mitochondrial membrane and increasing apoptotic threshold). AMX0035 is designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. Preclinical studies have provided evidence that AMX0035 may reduce cell death and improve cellular function, also supporting the synergistic effect of AMX0035 compared to individual compounds. Currently, the drug is in the Phase II stage of its development for the treatment of Alzheimer's disease.
* CT-1812: Cognition Therapeutics
Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer's disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer's-disease.
* CM383: KeyMed Biosciences
CM383 is an investigational drug being developed for the treatment of Alzheimer's disease. It is a small molecule designed to target the underlying mechanisms of the disease, specifically by modulating the immune response and reducing neuroinflammation, which are key factors in Alzheimer's pathology. CM383 works by targeting the immune system's response to amyloid-beta plaques, which are characteristic of Alzheimer's disease. It aims to enhance the brain's ability to clear these plaques and improve neuronal health. This approach is distinct from many traditional Alzheimer's treatments that primarily focus on amyloid plaque reduction or cholinergic modulation. Currently, the drug is in the Phase I stage of development to treat Alzheimer's-disease.
The Dementia Associated With Alzheimer's Disease Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Dementia Associated With Alzheimer's Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dementia Associated With Alzheimer's Disease Treatment.
* Dementia Associated With Alzheimer's Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Dementia Associated With Alzheimer's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dementia Associated With Alzheimer's Disease market.
Learn more about Dementia Associated With Alzheimer's Disease Drugs opportunities in our groundbreaking Dementia Associated With Alzheimer's Disease research and development projects @ Dementia Associated With Alzheimer's Disease Unmet Needs [https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Dementia Associated With Alzheimer's Disease Companies
BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.
Dementia Associated With Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Dementia Associated With Alzheimer's Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in Dementia Associated With Alzheimer's Disease treatment by visiting our website. Stay informed about how we're transforming the future of Central Nervous System @ Dementia Associated With Alzheimer's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Dementia Associated With Alzheimer's Disease Pipeline Report
* Coverage- Global
* Dementia Associated With Alzheimer's Disease Companies- BioVie, Bristol Myers Squibb, Cognition Therapeutics, Alector, TrueBinding, KeyMed Biosciences, Alzinova, AriBio Co., Ltd., Eli Lilly & Co., AbbVie Inc., Allyx Therapeutics, Inc., Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc. and others.
* Dementia Associated With Alzheimer's Disease Pipeline Therapies- ITI-1284, Brexpiprazole, ONO-2020, ML-007C-MA, KarXT, Quetiapine Fumarate, DMB-I (Dimebon), aripiprazole, PYM50028, Crenezumab, and others.
* Dementia Associated With Alzheimer's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Dementia Associated With Alzheimer's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Dementia Associated With Alzheimer's Disease Pipeline on our website @ Dementia Associated With Alzheimer's Disease Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/dementia-associated-with-alzheimers-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Dementia Associated With Alzheimer's Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Dementia Associated With Alzheimer's Disease- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NE3107: BioVie
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CT-1812: Cognition Therapeutics
* Early Stage Products (Phase I)
* CM383: KeyMed Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Dementia Associated With Alzheimer's Disease Key Companies
* Dementia Associated With Alzheimer's Disease Key Products
* Dementia Associated With Alzheimer's Disease- Unmet Needs
* Dementia Associated With Alzheimer's Disease- Market Drivers and Barriers
* Dementia Associated With Alzheimer's Disease- Future Perspectives and Conclusion
* Dementia Associated With Alzheimer's Disease Analyst Views
* Dementia Associated With Alzheimer's Disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dementia-associated-with-alzheimers-disease-pipeline-drugs-report-2025-a-strategic-overview-of-clinical-advancements-and-drug-pipeline-growth-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dementia-associated-with-alzheimers-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dementia Associated With Alzheimer's Disease Pipeline Drugs Report 2025: A Strategic Overview of Clinical Advancements and Drug Pipeline Growth by DelveInsight here
News-ID: 4204536 • Views: …
More Releases from ABNewswire
Cabinets 4 Less Tempe, AZ Opens New Showroom Offering Affordable Cabinet Solutio …
Cabinets 4 Less Tempe, AZ has opened a new showroom at 1840 E Warner Rd Suite 116, offering affordable and stylish cabinetry for kitchens, bathrooms, and home projects. The cabinet store provides homeowners, contractors, and designers with a wide selection of styles and finishes, quick order fulfillment, and personalized service to make high-quality cabinets accessible across the Tempe community.
TEMPE, AZ - September 30, 2025 - Cabinets 4 Less Tempe, AZ…
Non Muscle Invasive Bladder Cancer Pipeline 2025: Pioneering Clinical Developmen …
Non Muscle Invasive Bladder Cancer companies are Pfizer, Theralase Technologies, Protara Therapeutics, Zhuhai Beihai Biotech Co., Ltd, Vaxiion Therapeutics, Aura Biosciences, Ractigen Therapeutics, Tyra Biosciences, Hoffmann-La Roche, SURGE Therapeutics, CG Oncology, Inc., Trigone Pharma Ltd., Merck Sharp & Dohme LLC, and others.
With Non Muscle Invasive Bladder Cancer (NMIBC) increasingly impacting populations worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more…
Bardet-Biedl Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Glob …
DelveInsight's, "Bardet-Biedl Syndrome - Pipeline Insight, 2025," report provides comprehensive insights about 1+ companies and 1+ pipeline drugs in Bardet-Biedl Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Bardet-Biedl Syndrome (BBS) increasingly impacting populations worldwide and contributing…
Brain Metastases Pipeline 2025: Pioneering Clinical Advancements by 40+ Global L …
Brain Metastases companies are Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, and others.
With brain metastases increasingly prevalent worldwide and contributing to comorbid conditions such as diabetes, cardiovascular…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
